Fremanezumab vs placebo significantly reduced monthly migraine days and depressive symptoms in patients with migraine and comorbid major depressive disorder.

Hearing loss may cause up to one-third of dementia cases in older adults, making it an important risk factor to address.

The FDA has approved Xifyrm for use in adults for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics.

Intravenous thrombolysis in patients hospitalized for cervical artery dissection-related acute ischemic stroke increases the likelihood of home discharge.

Individuals with shorter leukocyte telomere length (LTL) have a higher incidence of stroke, dementia, and late-life depression (LLD).

HealthDay News — New mothers face a significant loss of uninterrupted sleep through week 13 postpartum, according to a study presented at SLEEP 2025, the annual meeting of the Associated Professional ...

A growing number of firearm suicides in the United States occur outside the home, most commonly in motor vehicles.

HealthDay News — Health care employment growth decreased during the pandemic but recovered by 2024, according to a research letter published online June 5 in the Journal of the American Medical ...

Dr L’Erario discusses neurologic care for TGD patients, highlighting key challenges, best practices, & steps toward more ...

Psilocybin therapy improved cognitive performance, reduced mood dysfunction, motor, and nonmotor symptoms in patients with Parkinson disease.

The FDA has accepted for review the resubmitted NDA for ND0612 for the treatment of motor fluctuations in patients with Parkinson disease.

Decreases in global cognition and executive function, as well as long-term persistent declines in those cognitive domains, are associated with incident HF.